{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:37:49Z","timestamp":1764081469589,"version":"3.45.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-01037-4","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:34:45Z","timestamp":1764081285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Simultaneous determination of iloperidone and its metabolites in rat plasma using a novel UPLC-MS\/MS method: an application for drug-drug interaction"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaohai","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-ai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"1037_CR1","doi-asserted-by":"publisher","first-page":"e22373","DOI":"10.1371\/journal.pone.0022373","volume":"6","author":"A-M Daniel","year":"2011","unstructured":"Daniel A-M, Peter A, Christian A-F, Benjamin G, Antonio I-LJ, Carlos AF, Mohamed NA. Levels of spending and resource allocation to HIV programs and services in Latin America and the Caribbean. PLoS ONE. 2011;6:e22373.","journal-title":"PLoS ONE"},{"key":"1037_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1358\/dot.2010.46.8.1509989","volume":"46","author":"JR Bishop","year":"2010","unstructured":"Bishop JR, Bishop DL. Iloperidone for the treatment of schizophrenia. Drugs Today (Barc). 2010;46:567\u201379.","journal-title":"Drugs Today (Barc)"},{"key":"1037_CR3","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1517\/17425255.2010.531259","volume":"6","author":"L Citrome","year":"2010","unstructured":"Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010;6:1551\u201364.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1037_CR4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0022-3565(24)37723-7","volume":"286","author":"AE Mutlib","year":"1998","unstructured":"Mutlib AE, Klein JT. Application of liquid chromatography\/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of Iloperidone. J Pharmacol Exp Ther. 1998;286:1285\u201393.","journal-title":"J Pharmacol Exp Ther"},{"key":"1037_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/03639045.2020.1742142","volume":"46","author":"D Suram","year":"2020","unstructured":"Suram D, Narala A, Veerabrahma K. Development, characterization, comparative Pharmacokinetic and pharmacodynamic studies of Iloperidone solid SMEDDS and liquisolid compact. Drug Dev Ind Pharm. 2020;46:587\u201396.","journal-title":"Drug Dev Ind Pharm"},{"key":"1037_CR6","doi-asserted-by":"crossref","unstructured":"Zhang F, Chu M, Liu J, Zhao Q, Zhu Y, Wu X. Shikonin suppresses cell tumorigenesis in gastric cancer associated with the inhibition of c-Myc and Yap-1. Comb Chem High Throughput Screen. 2023.","DOI":"10.2174\/0113862073254088231020082912"},{"key":"1037_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00210-023-02593-4","volume":"397","author":"M Rihan","year":"2024","unstructured":"Rihan M, Sharma SS. Inhibition of pyruvate kinase M2 (PKM2) by Shikonin attenuates isoproterenol-induced acute myocardial infarction via reduction in inflammation, hypoxia, apoptosis, and fibrosis. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:145\u201359.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1037_CR8","doi-asserted-by":"crossref","unstructured":"Song Y, Ding Q, Hao Y, Cui B, Ding C, Gao F. Pharmacological effects of shikonin and its potential in skin repair: a review. Molecules. 2023;28.","DOI":"10.3390\/molecules28247950"},{"key":"1037_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.toxlet.2017.09.014","volume":"281","author":"S Tang","year":"2017","unstructured":"Tang S, Chen A, Zhou X, Zeng L, Liu M, Wang X. Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay. Toxicol Lett. 2017;281:74\u201383.","journal-title":"Toxicol Lett"},{"issue":"Suppl 1","key":"1037_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4088\/JCP.10075su1.04","volume":"72","author":"L Citrome","year":"2011","unstructured":"Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72(Suppl 1):19\u201323.","journal-title":"J Clin Psychiatry"},{"key":"1037_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jchromb.2013.03.026","volume":"928","author":"M Jia","year":"2013","unstructured":"Jia M, Li J, He X, Liu M, Zhou Y, Fan Y, Li W. Simultaneous determination of Iloperidone and its two active metabolites in human plasma by liquid chromatography-tandem mass spectrometry: application to a Pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;928:52\u20137.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1037_CR12","doi-asserted-by":"publisher","first-page":"e17239","DOI":"10.1371\/journal.pone.0017239","volume":"6","author":"ZJ Zhang","year":"2011","unstructured":"Zhang ZJ, Tan QR, Tong Y, Wang XY, Wang HH, Ho LM, Wong HK, Feng YB, Wang D, Ng R, et al. An epidemiological study of concomitant use of Chinese medicine and antipsychotics in schizophrenic patients: implication for herb-drug interaction. PLoS ONE. 2011;6:e17239.","journal-title":"PLoS ONE"},{"key":"1037_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4155\/bio.13.25","volume":"5","author":"JM Parekh","year":"2013","unstructured":"Parekh JM, Sanyal M, Yadav M, Shrivastav PS. Stable-isotope Dilution LC-MS\/MS assay for determination of Iloperidone and its two major metabolites, P 88 and P 95, in human plasma: application to a bioequivalence study. Bioanalysis. 2013;5:669\u201386.","journal-title":"Bioanalysis"},{"key":"1037_CR14","doi-asserted-by":"publisher","first-page":"106073","DOI":"10.1016\/j.arabjc.2024.106073","volume":"18","author":"X Chen","year":"2025","unstructured":"Chen X, Hong F, Wu H, Shen Y, Xia H, Xu R-a, Shi L. Effects of Baicalein and Fangchinoline on abemaciclib metabolism in vivo and in vitro and molecular Docking analysis. Arab J Chem. 2025;18:106073.","journal-title":"Arab J Chem"},{"key":"1037_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.chroma.2012.12.071","volume":"1292","author":"N Ansermot","year":"2013","unstructured":"Ansermot N, Brawand-Amey M, Kottelat A, Eap CB. Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. J Chromatogr A. 2013;1292:160\u201372.","journal-title":"J Chromatogr A"},{"key":"1037_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12272-014-0361-1","volume":"38","author":"K Noh","year":"2014","unstructured":"Noh K, Jang YJ, Kwon KI, Kim E, Kang W. Quantitative determination of Amisulpride in rat plasma by HPLC\u2013MS\/MS. Arch Pharm Res. 2014;38:63\u20137.","journal-title":"Arch Pharm Res"},{"key":"1037_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/rcm.7907","volume":"31","author":"S Pandeti","year":"2017","unstructured":"Pandeti S, Rout TK, Tadigoppula N, Thota JR. Identification of stress degradation products of Iloperidone using liquid chromatography coupled with an orbitrap mass spectrometer. Rapid Commun Mass Spectrom. 2017;31:1324\u201332.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"1037_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/NDT.S37824","volume":"10","author":"JT Rado","year":"2014","unstructured":"Rado JT, Janicak PG. Long-term efficacy and safety of iloperidone: an update. Neuropsychiatr Dis Treat. 2014;10:409\u201315.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1037_CR19","doi-asserted-by":"crossref","unstructured":"Torres R, Czeisler EL, Chadwick SR, Stahl SM, Smieszek SP, Xiao C, Polymeropoulos CM, Birznieks G, Polymeropoulos MH. Efficacy and safety of iloperidone in bipolar mania: a double-blind, placebo-controlled study. J Clin Psychiatry. 2024;85.","DOI":"10.4088\/JCP.23m14966"},{"key":"1037_CR20","doi-asserted-by":"crossref","unstructured":"Danek PJ, Kuban W, Daniel WA. The effect of chronic iloperidone treatment on cytochrome P450 expression and activity in the rat liver: involvement of neuroendocrine mechanisms. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22168447"},{"key":"1037_CR21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1517\/17425255.2014.885504","volume":"10","author":"E Spina","year":"2014","unstructured":"Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014;10:721\u201346.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1037_CR22","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/aps.2016.96","volume":"37","author":"Q Pei","year":"2016","unstructured":"Pei Q, Huang L, Huang J, Gu JK, Kuang Y, Zuo XC, Ding JJ, Tan HY, Guo CX, Liu SK, Yang GP. Influences of CYP2D6(*)10 polymorphisms on the Pharmacokinetics of Iloperidone and its metabolites in Chinese patients with schizophrenia: a population Pharmacokinetic analysis. Acta Pharmacol Sin. 2016;37:1499\u2013508.","journal-title":"Acta Pharmacol Sin"},{"key":"1037_CR23","doi-asserted-by":"publisher","first-page":"116797","DOI":"10.1016\/j.taap.2023.116797","volume":"482","author":"Y Hu","year":"2024","unstructured":"Hu Y, Xie S, Xia H, Chen J, Yang Y, Zhan R. The effect of Shikonin on the metabolism of lapatinib in vitro, and in vivo. Toxicol Appl Pharmacol. 2024;482:116797.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1037_CR24","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/jphp.13288","volume":"72","author":"M Jin","year":"2020","unstructured":"Jin M, Shi D, Jin H, Zhou Z, Wang C. The inhibitory effects of Shikonin and \u03b2,\u03b2-dimethylacrylshikonin on Tramadol metabolism in vitro and in vivo. J Pharm Pharmacol. 2020;72:1232\u20138.","journal-title":"J Pharm Pharmacol"},{"key":"1037_CR25","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/13880209.2021.1964544","volume":"59","author":"T Lan","year":"2021","unstructured":"Lan T, Fang P, Ye X, Lan X, Xu RA. Evaluation of herb-drug interaction of ambrisentan with Shikonin based on UPLC-MS\/MS. Pharm Biol. 2021;59:1133\u20138.","journal-title":"Pharm Biol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01037-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01037-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01037-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:34:47Z","timestamp":1764081287000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-01037-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01037-4","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work had already been approved by The Institutional Animal Care and Use Committee (IACUC) of The First Affiliated Hospital of Wenzhou Medical University (Zhejiang, China) (Approval number: WYYY-IACUC-AEC-2023-036). The Sprague-Dawley rats were supplied from the Laboratory Animal Center of The First Affiliated Hospital of Wenzhou Medical University (Zhejiang, China), and informed consent from the owner has been obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}